Vanrx Pharmasystems has been selected to supply aseptic filling and lyophilizer loading systems for AB BioTechnologies’ new facility in the US.
AB BioTechnologies is developing a 23,000ft² manufacturing facility in Bloomington, Indiana.
The automated aseptic filling and lyophilization services will compliment AB’s existing offering of formulation, analytical services, lyophilization cycle development and GLP/tox manufacturing.
AB is expanding its services to support its customers in the development of new drug products from preclinical through clinical trials using a single provider.
Vanrx complete system includes SA25 aseptic filling workcell, accumulator and lyophilizer loader, which is claimed to be the first of its type in the US.
The company is claimed to be the only manufacturer to offer a gloveless robotic isolator system for aseptic filling and lyophilization of sterile injectable pharmaceuticals.
Vanrx aseptic filling workcells will help to produce liquid or freeze-dried drug products in different vial, syringe and cartridge formats.
AB will install Vanrx aseptic filling equipment within a Biologics Modular’s prefabricated modular cleanroom, which is attached to SP Scientific’s lyophilizer.
The fully integrated and automated aseptic filling system can be integrated with robotics, gloveless isolator and machine vision technologies.
AB BioTechnologies CEO Jeff Schwegman said: "The flexibility and aseptic assurance of the Vanrx system will enable us to provide exceptional service to pharmaceutical companies.
Vanrx CEO Chris Procyshyn said: "For a customer with Jeff's high level of knowledge to choose Vanrx is a vote of confidence in our approach. We share their view that more companies should be able to bring drugs that benefit patients to market.”
Image: Vanrx’s complete SA25 aseptic filling workcell system will support GMP manufacturing of preclinical and clinical liquid and lyophilized sterile injectables. Photo: courtesy of CNW Group/Vanrx Pharmasystems Inc.